%0 Journal Article
%T BETter together: exploiting BRD4-functions in transcription to inform rational combinations
%A Fabio Savarese
%A Norbert Kraut
%J Archive of "Oncoscience".
%D 2018
%R 10.18632/oncoscience.415
%X The identification of inhibitors of the BET family of bromodomain proteins (BETi) has fueled our knowledge about functions of their targets, the transcriptional regulators BRD2/3/4 and T, and this class of antitumor agents holds promise in clinical development [1]. However, even in pre-clinical models derived from hematological malignancies, which are in general more sensitive to BETi than those originating from solid cancers [2], use of BETi as single agents rarely results in strong apoptosis induction or tumor regressions at tolerated doses [1], underscoring the requirement for rational combination approaches
%K BRD4
%K BET inhibitors
%K CDK9
%K PARP
%K drug combinations
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049308/